Item 8.01. Other Events.



On June 23, 2021, BeiGene, Ltd. announced that the China National Medical
Products Administration (NMPA) has granted its anti-PD-1 antibody tislelizumab
approval for the first-line treatment of patients with advanced non-squamous
non-small cell lung cancer and conditional approval for the treatment of
patients with hepatocellular carcinoma who have been previously treated with at
least one systemic therapy. The full text of this press release is filed as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "China NMPA Approves

Tislelizumab in Non-Small Cell

Lung Cancer and Hepatocellular Carcinoma", issued

by BeiGene, Ltd. on June


                          23, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline


                          XBRL






--------------------------------------------------------------------------------


                                 Exhibit Index

   Exhibit No.            Description

       99.1                 Press Release titled "    China NMPA Approves

Tislelizumab in Non-Small


                          Cell Lung Cancer and Hepatocellular Carcinoma

", issued by BeiGene, Ltd.


                          on June 23, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses